Results 261 to 270 of about 38,200 (304)
Some of the next articles are maybe not open access.
Pharmacogenomics of adrenoceptors
Pharmacogenomics, 2004Adrenoceptors (ARs) consist of nine subtypes (alpha(1A)-, alpha(1B)-, alpha(1D)-, beta(1)-, beta(2)-, beta(3)-, alpha(2A)-, alpha(2B)- and alpha(2C)-AR), which are involved in a wide spectrum of physiological functions and are the site of action for a considerable percentage of currently prescribed therapeutics.
C, Flordellis +3 more
openaire +2 more sources
2009
Pharmacogenomics encompasses several major areas including the identification and analysis of variations of DNA and RNA that affect the efficacy and toxicity of drug therapy. It represents an integration of analytical approaches including DNA and RNA detection and quantitation which may be applied to either candidate genes or a global genome analysis.
Shilong, Zhong, Marjorie, Romkes
openaire +2 more sources
Pharmacogenomics encompasses several major areas including the identification and analysis of variations of DNA and RNA that affect the efficacy and toxicity of drug therapy. It represents an integration of analytical approaches including DNA and RNA detection and quantitation which may be applied to either candidate genes or a global genome analysis.
Shilong, Zhong, Marjorie, Romkes
openaire +2 more sources
Pharmacogenomics, 2015
Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels. Glinides stimulate insulin secretion by inhibiting ATP-sensitive potassium channels in the pancreatic β-cell membrane. Although
Miao, Chen, Cheng, Hu, Weiping, Jia
openaire +2 more sources
Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels. Glinides stimulate insulin secretion by inhibiting ATP-sensitive potassium channels in the pancreatic β-cell membrane. Although
Miao, Chen, Cheng, Hu, Weiping, Jia
openaire +2 more sources
Pharmacogenomics of hypertension
Current Opinion in Nephrology and Hypertension, 2003The emerging field of pharmacogenomics has the potential to fundamentally change the management of essential hypertension, a common, perhaps polygenic syndrome characterized by substantial inter-individual variability in drug responsiveness. As understanding of sequence diversity in the human genome progresses, the prospect grows for tailoring the ...
Peter E, Cadman, Daniel T, O'Connor
openaire +2 more sources
The pharmacogenomics of osteosarcoma
The Pharmacogenomics Journal, 2016Osteosarcoma (OS), the most common malignant tumor of bone, is presently treated with multidrug neoadjuvant chemotherapy protocols, which allow to cure 60-65% of patients but also induce toxicity events that cannot be predicted or efficiently prevented.
M, Serra, C M, Hattinger
openaire +2 more sources
2022
Historically genetics has not been considered when prescribing drugs for children. However, it is clear that genetics are not only an important determinant of disease in children but also of drug response for many important drugs that are core agents used in the therapy of common problems in children. Advances in therapy and in the ethical construct of
Michael J, Rieder +1 more
openaire +2 more sources
Historically genetics has not been considered when prescribing drugs for children. However, it is clear that genetics are not only an important determinant of disease in children but also of drug response for many important drugs that are core agents used in the therapy of common problems in children. Advances in therapy and in the ethical construct of
Michael J, Rieder +1 more
openaire +2 more sources
Pharmacogenomics of Antiretrovirals
Recent Patents on Anti-Infective Drug Discovery, 2008HIV infection is a serious but treatable disease, yet current treatment is limited by development of resistance and high rates of adverse drug reactions. Antiretroviral therapy is especially suitable for pharmacogenomic investigation as both drug exposure and treatment response can be reliably measured.
openaire +3 more sources
Pharmacogenomics and schizophrenia
European Journal of Pharmacology, 2000Although antipsychotic drugs are effective in alleviating schizophrenic symptoms, individual differences in patient response suggest that genetic components play a major role, and pharmacogenetic studies have indicated the possibility for a more individually based pharmacotherapy. The new field of pharmacogenomics, which focuses on genetic determinants
Y, Kawanishi, H, Tachikawa, T, Suzuki
openaire +2 more sources
Developmental pharmacogenomics
Pediatric Anesthesia, 2011SummaryInterindividual variability in the disposition and action associated with similar doses of a given medication is an inherent characteristic of both adult and pediatric populations. Genotype–phenotype relationships in infants and children must take into account the role that ontogeny plays in producing variability in both pharmacokinetics and ...
Kathleen A, Neville +3 more
openaire +2 more sources
Pharmacogenomics, 2009
Genetic polymorphisms for histamine-metabolizing enzymes are responsible for interindividual variation in histamine metabolism and are associated with diverse diseases. Initial reports on polymorphisms of histamine-related genes including those coding for the enzymes histidine decarboxylase (HDC), diamine oxidase (ABP1) and histamine N ...
Elena, García-Martín +4 more
openaire +2 more sources
Genetic polymorphisms for histamine-metabolizing enzymes are responsible for interindividual variation in histamine metabolism and are associated with diverse diseases. Initial reports on polymorphisms of histamine-related genes including those coding for the enzymes histidine decarboxylase (HDC), diamine oxidase (ABP1) and histamine N ...
Elena, García-Martín +4 more
openaire +2 more sources